Terms: = Uterine cancer AND PIK3R1, P27986, 5295, ENSG00000145675, p85-ALPHA, GRB1 AND Prognosis
11 results:
1. Genomic profile of Chinese patients with endometrial carcinoma.
Li J; Li X; Quan C; Li X; Wan C; Wu X
BMC Cancer; 2023 Sep; 23(1):888. PubMed ID: 37730563
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Evidence for Epithelial Origin of Mixed Ovarian Epithelial-Germ Cell Neoplasms: Report of 2 Cases and Review of Literature.
Hall KC; Post MD; Alldredge J; Aisner DL; Berning A
Int J Gynecol Pathol; 2023 Jul; 42(4):403-413. PubMed ID: 36305517
[TBL] [Abstract] [Full Text] [Related]
4. Genomic landscape of endometrial carcinomas of no specific molecular profile.
Momeni-Boroujeni A; Nguyen B; Vanderbilt CM; Ladanyi M; Abu-Rustum NR; Aghajanian C; Ellenson LH; Weigelt B; Soslow RA
Mod Pathol; 2022 Sep; 35(9):1269-1278. PubMed ID: 35365770
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial cancer Subrogate Molecular Classification.
Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
[TBL] [Abstract] [Full Text] [Related]
6. Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma.
Lazo de la Vega L; Samaha MC; Hu K; Bick NR; Siddiqui J; Hovelson DH; Liu CJ; Carter CS; Cho KR; Sciallis AP; Tomlins SA
Mol Cancer Res; 2019 Mar; 17(3):731-740. PubMed ID: 30610106
[TBL] [Abstract] [Full Text] [Related]
7. Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium.
Hsu AH; Lum MA; Shim KS; Frederick PJ; Morrison CD; Chen B; Lele SM; Sheinin YM; Daikoku T; Dey SK; Leone G; Black AR; Black JD
Cell Rep; 2018 Jul; 24(3):655-669. PubMed ID: 30021163
[TBL] [Abstract] [Full Text] [Related]
8. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; Zhang S; ; Lozy F; Sgroi DC; Vidal Bel A; Matias-Guiu X; Broaddus RR; Lu KH; Levine DA; Mutch DG; Goodfellow PJ; Salvesen HB; Mullikin JC; Bell DW
Cancer; 2017 Sep; 123(17):3261-3268. PubMed ID: 28485815
[TBL] [Abstract] [Full Text] [Related]
9. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
[TBL] [Abstract] [Full Text] [Related]
10. Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β.
Han G; Soslow RA; Wethington S; Levine DA; Bogomolniy F; Clement PB; Köbel M; Gilks B; DeLair D
Int J Gynecol Pathol; 2015 Jul; 34(4):323-33. PubMed ID: 25851704
[TBL] [Abstract] [Full Text] [Related]
11. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Matulonis U; Vergote I; Backes F; Martin LP; McMeekin S; Birrer M; Campana F; Xu Y; Egile C; Ghamande S
Gynecol Oncol; 2015 Feb; 136(2):246-53. PubMed ID: 25528496
[TBL] [Abstract] [Full Text] [Related]
